Key facts
- Notable investors include FACIT, HaloHealth, Ontario Bioscience Innovation Organization.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for NodeAI (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for NodeAI (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NodeAI (Decision/Risk Analysis)
Developer of a diagnostic platform designed to enhance lung cancer staging accuracy. The company's platform integrates artificial intelligence, machine learning, ultrasound image analysis, and automated report generation for lymph node detection and malignancy prediction, enabling healthcare professionals to improve diagnostic precision, reduce repeat biopsies, and streamline clinical workflows for better patient outcomes.
- Sector
- Healthcare
- HQ
- Hamilton, Canada
- Founded
- 2023
- Employees
- 4
- Website
- nodeai.ca/
- Ownership
- Privately Held (backing)
NodeAI (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NodeAI (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NodeAI (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.